Imunon Past Earnings Performance
Past criteria checks 0/6
Imunon's earnings have been declining at an average annual rate of -18.9%, while the Biotechs industry saw earnings growing at 12.7% annually. Revenues have been declining at an average rate of 13.3% per year.
Key information
-18.9%
Earnings growth rate
23.6%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | -13.3% |
| Return on equity | -145.8% |
| Net Margin | n/a |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Celsion changes name to Imunon (IMNN)
Sep 19Celsion says additional data shows placcine vaccine works against COVID-19 in animal model
Sep 01Celsion Q2 2022 Earnings Preview
Aug 12Celsion adds Moderna chief commercial officer as CEO
Jul 19Is Celsion (NASDAQ:CLSN) Using Debt Sensibly?
Dec 07
Is Celsion (NASDAQ:CLSN) Using Too Much Debt?
Aug 18What We Learned About Celsion's (NASDAQ:CLSN) CEO Compensation
Dec 01Celsion slips 4% on Q3 earnings miss
Nov 16Revenue & Expenses BreakdownBeta
How Imunon makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 0 | -20 | 10 | 11 |
| 30 Sep 23 | 0 | -28 | 11 | 0 |
| 30 Jun 23 | 0 | -31 | 13 | 0 |
| 31 Mar 23 | 0 | -31 | 14 | 0 |
| 31 Dec 22 | 1 | -36 | 14 | 12 |
| 30 Sep 22 | 1 | -27 | 12 | 0 |
| 30 Jun 22 | 1 | -26 | 11 | 0 |
| 31 Mar 22 | 1 | -26 | 11 | 0 |
| 31 Dec 21 | 1 | -21 | 11 | 0 |
| 30 Sep 21 | 1 | -20 | 10 | 0 |
| 30 Jun 21 | 1 | -22 | 9 | 0 |
| 31 Mar 21 | 1 | -22 | 9 | 0 |
| 31 Dec 20 | 1 | -21 | 8 | 0 |
| 30 Sep 20 | 1 | -22 | 7 | 0 |
| 30 Jun 20 | 1 | -19 | 7 | 0 |
| 31 Mar 20 | 1 | -20 | 8 | 0 |
| 31 Dec 19 | 1 | -17 | 8 | 0 |
| 30 Sep 19 | 1 | -8 | 9 | 0 |
| 30 Jun 19 | 1 | -7 | 9 | 0 |
| 31 Mar 19 | 1 | -10 | 10 | 0 |
| 31 Dec 18 | 1 | -12 | 10 | 0 |
| 30 Sep 18 | 1 | -22 | 9 | 0 |
| 30 Jun 18 | 1 | -23 | 8 | 0 |
| 31 Mar 18 | 1 | -20 | 6 | -3 |
| 31 Dec 17 | 1 | -21 | 6 | 0 |
| 30 Sep 17 | 1 | -21 | 6 | 4 |
| 30 Jun 17 | 1 | -22 | 6 | 8 |
| 31 Mar 17 | 1 | -21 | 6 | 15 |
| 31 Dec 16 | 1 | -22 | 7 | 15 |
| 30 Sep 16 | 1 | -22 | 6 | 15 |
| 30 Jun 16 | 1 | -20 | 6 | 13 |
| 31 Mar 16 | 1 | -21 | 7 | 14 |
| 31 Dec 15 | 1 | -22 | 7 | 15 |
| 30 Sep 15 | 1 | -23 | 7 | 16 |
| 30 Jun 15 | 1 | -26 | 8 | 17 |
| 31 Mar 15 | 1 | -27 | 8 | 17 |
| 31 Dec 14 | 1 | -25 | 9 | 15 |
| 30 Sep 14 | 1 | -23 | 8 | 12 |
| 30 Jun 14 | 1 | -20 | 7 | 10 |
| 31 Mar 14 | 1 | -13 | 7 | 9 |
| 31 Dec 13 | 1 | -13 | 7 | 9 |
| 30 Sep 13 | 0 | -17 | 7 | 11 |
| 30 Jun 13 | 0 | -19 | 7 | 12 |
Quality Earnings: IMNN is currently unprofitable.
Growing Profit Margin: IMNN is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: IMNN is unprofitable, and losses have increased over the past 5 years at a rate of 18.9% per year.
Accelerating Growth: Unable to compare IMNN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: IMNN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.9%).
Return on Equity
High ROE: IMNN has a negative Return on Equity (-145.77%), as it is currently unprofitable.